Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease

Parkinsonism & Related Disorders
Sergi FerréK Fuxe

Abstract

Evidence for a role of dopaminergic neurotransmission in the motor effects of adenosine antagonists, such as caffeine, is reviewed, based on the existence of specific antagonistic interactions between specific subtypes of adenosine and dopamine receptors in the striatum. Both adenosine A(1) and adenosine A(2A) receptor antagonists induce motor activation in rodents. At least a certain degree of dopaminergic activity is required to obtain adenosine antagonist-induced motor activation, with adenosine A(1) antagonists being the most sensitive and non-selective adenosine antagonists the most resistant to striatal dopamine depletion. When considering long-term treatment with adenosine antagonists concomitant administration of dopamine agonists might be required in order to obtain strong motor effects (cross-sensitization) and to avoid the development of telerance.

References

Dec 1, 1992·Neuroscience·S FerréB B Fredholm
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S FerreK Fuxe
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·S G Holtzman, I B Finn
Jan 1, 1993·Molecular Neurobiology·M ZoliK Fuxe
Apr 1, 1995·Pharmacology & Toxicology·B B Fredholm
Jan 1, 1993·Annual Review of Neuroscience·J A Gingrich, M G Caron
Feb 1, 1996·Brain : a Journal of Neurology·P P Pramstaller, C D Marsden
Mar 1, 1996·Trends in Pharmacological Sciences·K A JacobsonB B Fredholm

❮ Previous
Next ❯

Citations

Apr 12, 2008·Purinergic Signalling·Kathrin Sichardt, Karen Nieber
Aug 9, 2003·Neuropharmacology·Rosa E Moo-PucFrancisco Heredia-López
Jul 10, 2003·Neuroscience Letters·Jairo Villanueva-ToledoJosé L Góngora-Alfaro
Jul 12, 2005·Expert Opinion on Investigational Drugs·Peter Jenner
Jul 2, 2010·British Journal of Pharmacology·Sergi FerréSteven R Goldberg
Oct 16, 2015·Pharmacology, Biochemistry, and Behavior·Samantha J PodurgielJohn D Salamone
Jan 26, 2007·Pharmacology, Biochemistry, and Behavior·José L Bata-GarcíaJosé L Góngora-Alfaro
Dec 20, 2007·Journal of Neurochemistry·Sergi Ferré
Oct 16, 2015·European Journal of Medicinal Chemistry·Sarel J RobinsonAnna C U Lourens
Jun 19, 2012·Pharmacology, Biochemistry, and Behavior·Jessica L SanterreJohn D Salamone
Feb 17, 2007·Progress in Neurobiology·Patrizia PopoliMaria P Abbracchio
Sep 8, 2004·Neuroscience Letters·Leandre Carmem WilotAna Maria Oliveira Battastini
Jul 25, 2017·Chemical Biology & Drug Design·Lesetja J LegoabeGisella Terre'Blanche
Oct 27, 2006·Journal of Neural Transmission·K FuxeL F Agnati
Jul 10, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kjell FuxeLuigi Agnati
Mar 30, 2010·CNS Neuroscience & Therapeutics·K FuxeL F Agnati

❮ Previous
Next ❯

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.